Background
To date, the strongest genetic association identified for RA is with the HLA complex. Since Statsny's original observation in 1978 that RA is associated with HLA-DR4,3 many confirmatory studies have been published. It gradually became clear that different HLA-DR specificities were associated with RA in different ethnic groups. 4 The application of DNA sequencing and molecular based typing to detect HLA-DRB 1 alleles showed that those associated with RA (HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001, and *1402) shared a consensus amino acid sequence (QKRAA or QRRAA) at positions 70-74 of the third hypervariable region of the HLA-DRB1 chain-a position that influences its interaction with the T cell receptor. These studies led to the so called 'shared epitope' hypothesis, which unifies the various genetic associations in different populations. 5 treatment of RA will prevent the subsequent development of extra-articular disease. The two principal outcome measures in RA are the development of radiological erosions and the development of functional disability. Whilst there is a degree of overlap between these two measures, it is by no means complete. The genetic associations of 'disabling' RA are much weaker than those for 'erosive' RA.21-23 Thus, while patients who are shared epitope positive have about double the risk of developing erosions compared with those who are shared epitope negative, the risk of being functionally disabled at one year is the same in the two groups (Norfolk Arthritis Register data). It is therefore important that treatment decisions in RA should not centre solely on the aim of preventing erosions. Patients with no erosions may experience significant pain and disability, and they too require appropriate treatment.
Screening issues
Before a screening test is introduced, certain criteria require consideration.24 These criteria were developed for use when the introduction of population screening for disease (for example screening for hypertension) may be considered, but they can be applied equally well to the introduction of a screening test in early disease to predict future outcome. They are examined here in the context of genetic screening of patients with early RA in order to predict the development of erosions: (1) The population being screened should be at relatively high risk of developing the disease. Patients with early RA are at high risk (1 in 3) of developing erosions, so this criterion is satisfied.
(2) The undiagnosed disease should be of concern to the community being screened.
Whilst RA patients are often not aware of the significance oferosions, their physicians are aware.
Patient education can ensure that this criterion is met.
(3) The undiagnosed disease (erosions) should be more amenable to treatment at an early stage than it would be later. As outlined above, this point has not been proven in the patients who screen positive. (4) Individuals for whom the screening test is positive should be assured follow up evaluation. Genetic screening in RA patients should only be offered and interpreted by physicians in a position to provide expert long term management.
(5) The test should be highly sensitive and specific. Table 3 shows the sensitivity and specificity of the different genotypes. None satisfies the requirement to be both sensitive and specific (as shown in the receiver operator characteristic curves (figure)).
The most approprate test would be for the shared epitope.
(6) The test should be applicable and acceptable to a large number of individuals. Genetic screening would be performed using blood or mouth wash samples, which is generally acceptable. 
1-Specificity
Receiver operator characteristic (ROC) curves for predicting erosions-A: using 120 hospital based patients with RA from Birmingham; B: using 95 community based patients with RA from Norfolk. ROC curves plot sensitivity over (1 -specificity We still have much to learn about the significance of the presence and absence of RA associated genotypes in the prognosis and response to treatment of RA patients.
